

# Hypertonic Saline for MAC

NCT04921943

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	Oregon Health and Science University
<b>Enrollment</b>	50 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- At least 2 positive MAC sputum cultures in the last 12 months with at least one AFB positive sputum obtained within 12 weeks prior to randomization
- Meet American Thoracic Society (ATS)/ Infectious Disease Society of America (IDSA) 2007 pulmonary clinical disease criteria<sup>[1]</sup>
- Age 18 and older
- Diagnosis of Bronchiectasis and/or bronchiectatic findings evident on chest CT report
- Ability to provide informed consent

### Exclusion (8)

- Any patient who is unwilling or unable to provide consent or to comply with this protocol
- Cavitary NTM disease
- Patients who are currently taking or within the prior 6 months received any of the following: bedaquiline, or any component of ATS/IDSA multi-drug recommended therapy (macrolide, ethambutol, rifampin) for MAC treatment
- Diagnosis of HIV
- Diagnosis of Cystic fibrosis
- ... and 3 more (see full listing online)

## Locations (3 total)

---

NYU Langone Health, New York, New York, United States  
Oregon Health & Science University, Portland, Oregon, United States  
University Health Network, Toronto, Ontario, Canada